NASDAQ:SPRO | Free Cash Flow | Spero Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2015-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31$15.86M
2025-12-31-$8.35M
2025-03-31-$4M
2024-12-31-$23.4M
2024-03-31$5.94M
2023-12-31-$17.49M
2023-03-31-$12.85M
2022-12-31$44.48M
2022-03-31-$28.22M
2021-12-31-$27.35M
2021-03-31-$15.48M
2020-12-31-$16.38M$12,000.00-$16.4M
2020-03-31-$23.33M$79,000.00-$23.41M
2019-12-31-$17.37M$129,000.00-$17.5M
2019-03-31-$10.92M$81,000.00-$11.01M
2018-12-31-$13.51M$2.41M-$15.92M
2018-03-31-$11.96M
2017-12-31-$12.74M
2017-03-31-$6.98M
2016-12-31-$9.2M$261,000.00-$9.47M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$12.62M
2024-12-31-$23.44M
2023-12-31-$33M
2022-12-31-$7.73M
2021-12-31-$64.35M
2020-12-31-$85.87M$157,000.00-$86.03M
2019-12-31-$50.02M$314,000.00-$50.33M
2018-12-31-$39.63M$2.44M-$42.06M
2017-12-31-$39.11M$27,000.00-$39.14M
2016-12-31-$28.96M$830,000.00-$29.79M
2015-12-31-$9.61M$232,000.00-$9.84M

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.